Eli Lilly (LLY) opened trading at $1,208.37, marking a 14.4% increase in stock value year to date, outperforming the S&P 500 index.

Q1 2026 Financial Highlights

The company reported earnings per share (EPS) of $8.55 for the first quarter of 2026, significantly surpassing consensus estimates of $6.97. Total revenue reached $19.80 billion, exceeding expectations of $17.82 billion and reflecting a remarkable 55.5% increase compared to the same quarter last year.

The substantial growth was primarily driven by sales of Mounjaro and Zepbound, both of which accounted for nearly 65% of Eli Lilly’s total Q1 revenues. As a new addition to its lineup, Lilly launched its oral GLP-1 drug, Foundayo, which is expected to elevate GLP-1 contributions past 65% in Q2.

Diversification Efforts and Product Portfolio

Eli Lilly is actively diversifying its portfolio beyond GLP-1 medications to reduce dependency on its obesity treatments. The company has developed several non-GLP-1 drugs, including:

  • Omvoh for inflammatory bowel disease
  • Jaypirca for specific blood cancers
  • Ebglyss for atopic dermatitis
  • Kisunla targeting early Alzheimer's
  • Inluriyo for metastatic breast cancer

Notably, Jaypirca has seen a boost when the FDA expanded its label for patients with relapsed or refractory CLL/SLL towards the end of 2025, and the CHMP recommended broader approval for CLL therapy in Europe. The FDA is expected to announce a further label expansion decision for Jaypirca later this year.

Acquisitions and Market Position

The company has committed over $20 billion in acquisitions and partnerships in 2026, focusing on areas such as oncology, neuroscience, cardiovascular disease, gene editing, and vaccines, indicating a strong strategy for long-term diversification.

Trading at 30.67 times its forward earnings, LLY remains above the industry average of 18.76 but below its five-year mean of 34.56. The current market capitalization stands at $1.14 trillion. Full-year EPS estimates for 2026 have risen from $33.86 to $35.67, and for 2027, they have increased from $42.56 to $44.61.

Institutional ownership of LLY is recorded at 82.53%, and notable shareholder World Investment Advisors expanded its stake by 12.1% in Q1 2026. Analyst sentiment remains largely favorable; Goldman Sachs has assigned a buy rating with a price target of $1,283.